LEVITRA® 20mg Special Drug Use Investigation (Long-term)
Overview
This investigation targets either the patients of 18 years-old or older and under 65 years-old with organic or mixed erectile dysfunction (ED) who cannot obtain sufficient efficacy by dose 10mg of Levitra, and the target patients dose is increased to Levitra 20mg. This investigation will be limited to the patients whose tolerability of Levitra 10mg is judged to be no problem.
Full Title of Study: “LEVITRA® 20mg Special Drug Use Investigation (Long-term)”
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: March 2010
Interventions
- Drug: Vardenafil, (Levitra, BAY38-9456)
- Patients under daily life treatment receiving Levitra according to local drug information.
Arms, Groups and Cohorts
- Group 1
Clinical Trial Outcome Measures
Primary Measures
- Efficacy of patients with LEVITRA treatment
- Time Frame: After 6 months
Secondary Measures
- LEVITRA treatment improved the patient’s erection
- Time Frame: After 6 months
- LEVITRA improved the patient’s erection after Minimum and Maximum Intervals between LEVITRA intake and the start of intercourse
- Time Frame: After 6 months
- Reporting a second successful intercourse within 24 hours of dosing
- Time Frame: After 6 months
- Patients prefer LEVITRA over last Erectile Dysfunction treatment
- Time Frame: After 6 months
- Tolerability of patients with LEVITRA treatment
- Time Frame: After 6 months
Participating in This Clinical Trial
Inclusion Criteria
- This investigation targets either the patients of 18 years-old or older and under 65 years-old with organic or mixed erectile dysfunction who cannot obtain sufficient efficacy by dose 10mg of Levitra, and the target patients dose is increased to Levitra 20mg. This investigation will be limited to the patients whose tolerability of Levitra 10mg is judged to be no problem.
Gender Eligibility: Male
Minimum Age: 18 Years
Maximum Age: 64 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Bayer
- Provider of Information About this Clinical Study
- Medical Director, Bayer Yakuhin Ltd
- Overall Official(s)
- Bayer Study Director, Study Director, Bayer
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.